Text Size:AAA

人 CD70/CD27L/TNFSF7 基因ORF全长cDNA克隆(表达载体), N-Flag 标签

产品数据评论实验方法
描述: Active  
表达宿主: Human Cells  
  • Slide 1
10780-H01H-50
10780-H01H-5
10780-H01H-100
50 µg 
5 µg 
100 µg 
Add to Cart
表达宿主: Human Cells  
  • Slide 1
51129-M04H-50
51129-M04H-200
50 µg 
200 µg 
Add to Cart
表达宿主: Human Cells  
  • Slide 1
80161-R01H-50
80161-R01H-100
50 µg 
100 µg 
Add to Cart
表达宿主: Human Cells  
  • Slide 1
80161-R07H-50
80161-R07H-20
50 µg 
20 µg 
Add to Cart

CD70/CD27L/TNFSF7 cDNARelated Products

Related Products

Featured Reagent Products

CD70/CD27L/TNFSF7 cdna-clone 研究背景

CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.

Immune Checkpoint
Immune Checkpoint Proteins
Immune Checkpoint Targets   Co-stimulatory Immune Checkpoint Targets

Immunotherapy   Cancer Immunotherapy   Targeted Therapy

 CD70/CD27L/TNFSF7 cdna-clone 参考资料
  • Adam PJ, et al. (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer. 95(3): 298-306.
  • Keller AM, et al. (2007) Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proc Natl Acad Sci U S A. 104(14): 5989-94.
  • Grewal IS. (2008) CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets. 12(3): 341-51.
  • Boursalian TE, et al. (2009) Targeting CD70 for human therapeutic use. Adv Exp Med Biol. 647: 108-19.
  • 请注意:所有产品都是“仅用于科研,而不能用于诊断或治疗用途”